Quantbot Technologies LP Purchases New Holdings in Humana Inc. (NYSE:HUM)

Quantbot Technologies LP acquired a new stake in Humana Inc. (NYSE:HUM) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 31,584 shares of the insurance provider’s stock, valued at approximately $10,004,000. Humana accounts for approximately 0.4% of Quantbot Technologies LP’s investment portfolio, making the stock its 29th biggest position.

Several other large investors have also recently made changes to their positions in HUM. Mendota Financial Group LLC raised its position in Humana by 9.2% in the second quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock worth $119,000 after acquiring an additional 27 shares during the period. Capital Advisors Ltd. LLC grew its holdings in Humana by 17.0% during the second quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock valued at $80,000 after purchasing an additional 31 shares during the period. CarsonAllaria Wealth Management Ltd. increased its position in Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after buying an additional 39 shares during the last quarter. Moors & Cabot Inc. raised its stake in shares of Humana by 2.5% in the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after buying an additional 40 shares during the period. Finally, Harbour Investments Inc. lifted its position in shares of Humana by 10.5% during the 2nd quarter. Harbour Investments Inc. now owns 432 shares of the insurance provider’s stock valued at $161,000 after buying an additional 41 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

HUM opened at $304.18 on Tuesday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $36.63 billion, a P/E ratio of 26.94, a PEG ratio of 2.35 and a beta of 0.52. The stock has a 50-day moving average price of $276.61 and a 200-day moving average price of $330.51. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $527.18.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities analysts predict that Humana Inc. will post 15.86 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.16%. The ex-dividend date is Tuesday, December 31st. Humana’s payout ratio is presently 31.36%.

Analyst Ratings Changes

Several research firms have commented on HUM. Sanford C. Bernstein raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective on the stock in a report on Tuesday, October 8th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a report on Thursday, October 3rd. KeyCorp began coverage on Humana in a report on Friday, October 11th. They issued a “sector weight” rating for the company. Truist Financial dropped their price objective on Humana from $400.00 to $260.00 and set a “hold” rating on the stock in a report on Friday, October 11th. Finally, UBS Group decreased their price target on Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research report on Friday, October 4th. Twenty equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Humana presently has a consensus rating of “Hold” and an average target price of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.